Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.-论文-万方医学网

第一作者： Meletios A,Dimopoulos

第一单位： From the National and Kapodistrian University of Athens, Athens (M.A.D.); Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias I Pujol, Barcelona (A.O.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona (J.S.-M.) - both in Spain; Karolinska Institute and the Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.); Tom Baker Cancer Centre, University of Calgary, Calgary, AB (N.J.B.), and the Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto (D.R.) - both in Canada; Levine Cancer Institute-Carolinas HealthCare System, Charlotte, NC (S.Z.U.); the Department of Haematology, University College London Hospitals NHS Trust, London (N.R.); the Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); the Department of Hematology and Stem Cell Transplantation, Poznan University of Medical Sciences, Poznan, Poland (M.K.); the Department of Hematology, Japanese Red Cross Medical Center, Tokyo (K.S.); Vejle Hospital and University of Southern Denmark, Vejle (T.P.), and Genmab, Copenhagen (S.L.) - both in Denmark; the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.); the Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem (D.B.Y.); Dana-Farber Cancer Institute, Harvard Medical School, Boston (P.G.R.); University Hospital Heidelberg and the German Cancer Research Center, Heidelberg, Germany (H.G.); Janssen Research and Development, Spring House, PA (N.Z.K., L.O., C.C., X.Q., M.G., T.A.); and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France (P.M.).

作者： Meletios A,Dimopoulos ^[1] ; Albert,Oriol ^[1] ; Hareth,Nahi ^[1] ; Jesus,San-Miguel ^[1] ; Nizar J,Bahlis ^[1] ; Saad Z,Usmani ^[1] ; Neil,Rabin ^[1] ; Robert Z,Orlowski ^[1] ; Mieczyslaw,Komarnicki ^[1] ; Kenshi,Suzuki ^[1] ; Torben,Plesner ^[1] ; Sung-Soo,Yoon ^[1] ; Dina,Ben Yehuda ^[1] ; Paul G,Richardson ^[1] ; Hartmut,Goldschmidt ^[1] ; Donna,Reece ^[1] ; Steen,Lisby ^[1] ; Nushmia Z,Khokhar ^[1] ; Lisa,O'Rourke ^[1] ; Christopher,Chiu ^[1] ; Xiang,Qin ^[1] ; Mary,Guckert ^[1] ; Tahamtan,Ahmadi ^[1] ; Philippe,Moreau ^[1] ; POLLUX Investigators

作者单位： From the National and Kapodistrian University of Athens, Athens (M.A.D.); Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias I Pujol, Barcelona (A.O.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona (J.S.-M.) - both in Spain; Karolinska Institute and the Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.); Tom Baker Cancer Centre, University of Calgary, Calgary, AB (N.J.B.), and the Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto (D.R.) - both in Canada; Levine Cancer Institute-Carolinas HealthCare System, Charlotte, NC (S.Z.U.); the Department of Haematology, University College London Hospitals NHS Trust, London (N.R.); the Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); the Department of Hematology and Stem Cell Transplantation, Poznan University of Medical Sciences, Poznan, Poland (M.K.); the Department of Hematology, Japanese Red Cross Medical Center, Tokyo (K.S.); Vejle Hospital and University of Southern Denmark, Vejle (T.P.), and Genmab, Copenhagen (S.L.) - both in Denmark; the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.); the Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem (D.B.Y.); Dana-Farber Cancer Institute, Harvard Medical School, Boston (P.G.R.); University Hospital Heidelberg and the German Cancer Research Center, Heidelberg, Germany (H.G.); Janssen Research and Development, Spring House, PA (N.Z.K., L.O., C.C., X.Q., M.G., T.A.); and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France (P.M.). ^[1]

主题词老年人(Aged);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);地塞米松(Dexamethasone);无病生存(Disease-Free Survival);抗药性, 肿瘤(Drug Resistance, Neoplasm);人类(Humans);Kaplan-Meiers评估(Kaplan-Meier Estimate);中年人(Middle Aged);多发性骨髓瘤(Multiple Myeloma);复发(Recurrence);沙立度胺(Thalidomide)

DOI 10.1056/NEJMoa1607751

PMID 27705267

发布时间 2024-09-11

检索历史清除

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

The New England journal of medicine

相似文献

The New England journal of medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

The New England journal of medicine

相似文献

The New England journal of medicine

相关期刊

检索历史清除